The Healthy Aging and Senile Dementia program at Washington University School of Medicine in St. Louis has received $32 million over five years from the National Institute on Aging, part of the National Institutes of Health. The award keeps the study running through 2031, its 45th year, and shifts more of its attention toward preventing Alzheimer's and finding ways to treat it. The program began in the 1970s under neurologist Leonard Berg, MD, who wanted to understand the memory problems he was seeing in older patients rather than writing them off as normal aging. It has enrolled more than 1,877 people since then.
John C. Morris, MD, who has led the program since 1998, said the work has shown that Alzheimer's starts silently in the brain long before memory fails. The stated goal now is to stop the disease process before brain cells die, and to do that for all groups, since the disease occurs across races and ethnicities. The study's history includes the Clinical Dementia Rating, developed by Berg and colleagues and later refined by Morris, which is described in the source as the worldwide standard for determining whether dementia is present and how severe it is.
The new funding will examine whether some Alzheimer's biomarkers vary between Black and white participants, which would suggest that diagnostic tools may not perform equally well across racial groups. To address the long-standing imbalance in clinical research, the team plans to expand a pilot study in north St. Louis from about 40 participants to 300, with a wider range of education, income and health histories. A mobile clinic will bring data and blood and tissue collection into neighborhoods, and volunteers can be connected to health services if they need them. Morris said mistrust of medical institutions and practical barriers such as transportation have kept many community members out of research, and that the approach is meant to bring the research to them.
The second goal is to follow patients receiving newly available Alzheimer's treatments in routine clinical care, outside the controlled setting of clinical trials. The source notes that these therapies have been shown to slow progression in some people, and the researchers want to learn how they perform in everyday practice.
A research participant profiled in the article, Nicole Garrison, a pharmacist from Lake St. Louis, has watched Alzheimer's affect several generations of her family and has been in the Knight ADRC research since 2025. She has taken part in cognitive testing, brain imaging, blood draws and spinal taps, and she has publicly urged policymakers to expand access to blood-based tests, which are far less invasive. She said she does not expect to benefit personally, but hopes future generations will.